Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/5/2025

Treatment of Pseudomembranous Colitis

Immediate Management Steps

  • Discontinuing the inciting antibiotic immediately upon suspicion of C. difficile infection is crucial, as continued use significantly increases recurrence risk, and switching to agents less commonly associated with CDI such as parenteral aminoglycosides, sulfonamides, macrolides, vancomycin, or tetracycline/tigecycline is recommended if ongoing antibiotic therapy is essential 1

First-Line Antibiotic Therapy

  • Oral metronidazole is effective for mild-to-moderate disease, with advantages including lower cost and reduced selection pressure for vancomycin-resistant enterococci 1
  • Metronidazole has equivalent efficacy to vancomycin in non-severe cases with 97% cure rates, though it is inferior in severe disease 2

Management of Severe-Complicated Disease

  • Urgent surgical consultation is mandatory for patients showing signs of systemic toxicity, peritonitis, or worsening despite medical therapy 1

Recurrent Disease Management

  • Consider extended/pulsed vancomycin or fidaxomicin before considering fecal microbiota transplantation, as fidaxomicin and bezlotoxumab significantly reduce recurrence rates compared to standard vancomycin 3 4 1
  • Fecal microbiota transplantation (FMT) should be considered after failure of three courses of antibiotics, with FMT showing 92% clinical resolution across studies 3 4
  • For FMT failure in pseudomembranous colitis specifically, repeat FMT every 3 days until resolution of pseudomembranes has been successful 3 4

Critical Pitfalls to Avoid

  • Do not perform "test of cure" after treatment, as 56% of successfully treated patients asymptomatically shed C. difficile spores for up to 6 weeks 6
  • Do not repeat testing after initiating treatment unless there are clear clinical changes, as test positivity does not correlate with treatment failure 1
  • Do not treat asymptomatic carriage with C. difficile 6
  • Distinguish recurrent CDI from post-infectious irritable bowel syndrome, which can cause symptoms in up to 35% of patients during the first 2 weeks and 4.3% beyond 3 months 6